Logos Global Management’s Xenon Pharmaceuticals XENE Stock Holding History

Logos Global Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26.2M	Buy	+450,000	New	+$20.7M	1.31%	26
2025 Q2	–	Sell	-650,000	Closed	-$21.8M	–	62
2025 Q1	$21.8M	Buy	+650,000	New	+$24.7M	3.88%	7
2024 Q3	–	Sell	-375,000	Closed	-$14.6M	–	70
2024 Q2	$14.6M	Buy	+375,000	New	+$15M	1.18%	25
2024 Q1	–	Sell	-150,000	Closed	-$6.91M	–	72
2023 Q4	$6.91M	Sell	150,000 -300,000	-67%	-$10.6M	0.64%	36
2023 Q3	$15.4M	Buy	450,000 +175,000	+64%	+$6.55M	2.05%	17
2023 Q2	$10.6M	Sell	275,000 -625,000	-69%	-$24.8M	1.44%	22
2023 Q1	$32.2M	Hold	900,000	–	–	4.61%	6
2022 Q4	$35.5M	Buy	900,000 +400,000	+80%	+$14.6M	4.16%	7
2022 Q3	$18.1M	Buy	+500,000	New	+$18M	2.22%	17

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Logos Global Management's XENE Position: Q1 2026 in Review

Logos Global Management opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 450,000 shares worth $26.2M. The stake represents 1.31% of the portfolio and ranks #26 among its holdings. This is a return to the name: Logos Global Management previously reported a position in XENE as recently as Q1 2025.

Logos Global Management first reported a position in XENE in Q3 2022 and has held it in 9 quarters since. The position peaked at $35.5M in Q4 2022. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Logos Global Management held 450,000 shares of Xenon Pharmaceuticals worth $26.2M as of Q1 2026.
Xenon Pharmaceuticals was a new Logos Global Management position in Q1 2026.
Xenon Pharmaceuticals made up 1.31% of Logos Global Management's portfolio in Q1 2026, its #26 holding.
Logos Global Management first reported a position in Xenon Pharmaceuticals in Q3 2022 and has held it in 9 quarters since.
Logos Global Management's Xenon Pharmaceuticals position peaked at $35.5M in Q4 2022.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.